Can Crinetics Pharmaceuticals cover its short-term obligations?

Its current ratio is 18.60 — current assets exceed current liabilities.

Where does Crinetics Pharmaceuticals's balance sheet data come from?

Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Crinetics Pharmaceuticals CRNX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$115.14M+20.1%	$102.34M-61.5%	$112.2M-64.8%	$53.73M-82.2%	$95.87M-75.8%
Short-term investments	$1.18B-0.2%	$926.35M-15.0%	$981.39M+79.9%	$1.14B+104%	$1.18B+134%
Restricted cash	$800K+60.0%	$0-100%	$500K-61.5%	$500K-61.5%	$500K-61.5%
Accounts receivable, net	——	——	——	——	$0—
Inventories	——	——	——	——	$0—
Work in process	——	——	——	——	——
Finished goods	——	——	——	——	——
Prepaid expenses and other current assets	$22.36M+36.1%	$17.84M-14.3%	$28.48M+90.9%	$20.4M+72.6%	$16.43M+1.0%
Trading assets	——	——	——	——	——
Accrued investment income	——	——	——	——	——
Total current assets	$1.32B+2.4%	$1.05B-23.8%	$1.12B+27.8%	$1.22B+39.2%	$1.29B+40.8%
Property and equipment, net	$13.5M+6.9%	$14.3M+18.5%	$14.38M+22.8%	$14.67M+19.8%	$12.63M+6.4%
Accumulated depreciation	——	——	——	——	——
Operating lease right-of-use assets	8.6%-4,269,399,991%	8.6%-4,350,699,991%	8.6%-4,426,599,991%	4,190,200,000%-310,800,000%	4,269,400,000%-306,600,000%
Other non-current assets	——	——	——	——	$14.15M+608%
Available-for-sale securities	——	——	——	——	——
Total assets	$1.4B+2.9%	$1.13B-21.5%	$1.2B+27.6%	$1.29B+37.8%	$1.36B+39.2%
Accounts payable	$12.88M-59.3%	$22.61M+286%	$6.11M-66.6%	$38.09M+58.7%	$31.62M+10.2%
Accrued expenses	——	——	——	——	——
Deferred revenue	$1.27M-42.4%	$1.24M-43.2%	$1.64M-68.4%	$1.9M-55.9%	$2.21M-10.4%
Operating lease liabilities, current	$6.54M-5.0%	$6.49M-9.3%	$6.44M-13.1%	$6.61M-11.2%	$6.88M+18.8%
Contract liabilities	——	——	——	——	——
Accrued interest	——	——	——	——	——
Total current liabilities	$71.09M+24.0%	$85.07M+42.5%	$74.16M+38.4%	$68.4M+25.8%	$57.31M+10.7%
Operating lease liabilities, non-current	$41.32M-6.0%	$42.05M-5.6%	$42.7M-5.4%	$43.33M-5.6%	$43.94M-5.9%
Operating Lease Liabilities (Total)	$47.86M-5.8%	$48.54M-6.2%	$49.14M-6.5%	$49.94M-6.3%	$50.82M-3.2%
Other non-current liabilities	$4.93M+179%	$3.24M—	$2.89M—	$2.33M—	$1.77M—
Total liabilities	$120.68M+12.4%	$134.17M+22.2%	$123.86M+18.6%	$118.05M+12.7%	$107.33M+4.0%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	200M-91.3%	200M-91.2%	200M-88.3%	2.3B+43.6%	2.3B+44.2%
Retained earnings	-$1.55B-47.3%	-$1.42B-48.9%	-$1.29B-48.5%	-$1.16B-46.5%	-$1.05B-45.6%
Accumulated other comprehensive income (loss)	-$1.25M-163%	$1.87M+93.7%	$2.19M+7.7%	$1.62M+953%	$2M+1,235%
Total stockholders' equity	$1.28B+2.1%	$992.08M-25.1%	$1.07B+28.7%	$1.17B+41.0%	$1.25B+43.3%
Total liabilities and stockholders' equity	$1.4B+2.9%	$1.13B-21.5%	$1.2B+27.6%	$1.29B+37.8%	$1.36B+39.2%
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——	——
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	——	——	——	——	——
Available-for-Sale Debt Securities - Fair Value by Maturity	——	——	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Cash Cash Equivalents And Short Term Investments	——	——	——	——	——
Finished goods	——	——	——	——	——
Other current assets	——	——	——	——	——
Prepaid expenses and other	——	——	——	——	——
Debt Securities (Trading and AFS) - Cost Basis	——	——	——	——	——
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)	——	——	——	——	——
Net Investment in Lease	$39.79M-6.8%	$40.49M-6.9%	$41.15M-7.0%	$41.9M-6.9%	$42.69M-6.7%
Operating lease right-of-use assets	$39.79M-6.8%	$40.49M-6.9%	$41.15M-7.0%	$41.9M-6.9%	$42.69M-6.7%
Property, plant and equipment at cost	——	——	——	——	——
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$1.18B-0.2%	$926.35M-15.0%	$981.39M+79.9%	$1.14B+104%	$1.18B+134%
Operating Lease Right-of-Use Assets in Other Assets	$39.79M-6.8%	$40.49M-6.9%	$41.15M-7.0%	$41.9M-6.9%	$42.69M-6.7%
Prepaid Expenses, Non-Current	$24.82M—	——	——	——	——
Accrued Progress Collections and Price Adjustments	——	——	——	——	——
Accounts payable and other current liabilities (Note 11)	$37.49M+18.6%	$41.77M+94.6%	$33.67M+84.3%	$38.09M+58.7%	$31.62M+10.2%
Accrued compensation and related expenses	$25.79M+55.3%	$35.58M+23.2%	$32.4M+23.7%	$21.8M+7.0%	$16.61M+12.0%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Contract Liabilities, Non-Current	——	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Deferred revenue, net of current portion	——	——	——	——	——
Total debt	$47.86M-5.8%	$48.54M-6.2%	$49.14M-6.5%	$49.94M-6.3%	$50.82M-3.2%
Common Stock Par Value Per Share	——	——	——	——	——
Common Stock Shares Issued	——	——	——	——	——
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	——	——	——	——	——
Convertible Preferred Stock Issued Shares	——	——	——	——	——
Convertible Preferred Stock Outstanding Shares	——	——	——	——	——
Employee Benefit Trust	——	——	——	——	——
Common stock	$2.83B+22.9%	$2.41B+5.8%	$2.36B+38.9%	$2.33B+43.6%	$2.3B+44.2%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Number of Exercisable Options	——	——	——	——	——
Preferred Stock Par Value Per Share	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	——	——	——	——	——
Unrealized Gains on Investments	——	——	——	——	——
Unrealized Losses on Investments (Before Tax)	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	——	——	——	——	——
Cumulative Cost Basis	——	——	——	——	——
Accrued clinical trial costs	——	——	——	——	——
Accrued outside services and professional fees	——	——	——	——	——
Accrued research and development costs	——	——	——	——	——
Additional sales milestones	——	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——	——
Gross Unrealized Gains	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——	——
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Common stock, par value (in dollars per share)	——	——	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——	——
Common Stock Shares Held In Employee Trust	——	——	——	——	——
Common stock, shares issued (in shares)	——	——	——	——	——
Common Stock, Shares, Outstanding	——	——	——	——	——
Cost or Amortized Cost	——	——	——	——	——
Available-for-sale securities, allowance for credit loss	——	——	——	——	——
Less than 12 months	——	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	——	——	——	——	——
Estimated Fair Value	——	——	——	——	——
Deferred compensation plan assets	——	——	——	——	——
Deferred compensation plan	——	——	——	——	——
Interest receivable on interest rate and cross currency swaps	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Thereafter	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Loyal peferred stock	——	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——	——
Other accrued liabilities	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	——	——	——	——	——
Preferred Stock, Shares Authorized	——	——	——	——	——
Preferred Stock, Shares Issued	——	——	——	——	——
Preferred Stock, Shares Outstanding	——	——	——	——	——
Prepaid clinical costs	——	——	——	——	——
Prepaid expenses and other assets, net of current portion	——	——	——	——	——
Prepaid research and development costs	——	——	——	——	——
Prepaid subscriptions	——	——	——	——	——
Sale of stock, price per share (in dollars per share)	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Crinetics Pharmaceuticals cover its short-term obligations?: Its current ratio is 18.60 — current assets exceed current liabilities.
Where does Crinetics Pharmaceuticals's balance sheet data come from?: Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.